Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Paclitaxel-Coated PAD Devices Under US FDA Scrutiny

Executive Summary

The agency sent a letter to health-care providers stating that it is investigating reports of an elevated risk of death for patients starting two years after treatment with paclitaxel-coated balloons or paclitaxel-eluting stents. But FDA is not taking any regulatory action at this point.

You may also be interested in...



FDA Tells Providers To Limit Use Of Paclitaxel-Coated Stents

New US FDA analysis of paclitaxel-coated devices to treat peripheral arterial disease matches previous reports of an increased death risk tied to use of the devices. The agency is encouraging providers to look to other treatment options while analysis continues.

SCAI, Manufacturers Defend Peripheral Paclitaxel Devices Against Doubts

The Society for Cardiovascular Angiography and Interventions’ Vascular Disease Council says the recent meta-analysis finding a higher long-term mortality risk with paclitaxel-eluting peripheral devices can only be viewed as hypothesis-generating. The long-term risks of these devices should be investigated with patient-level data, SCAI argues. Several clinical data presentations at the recent LINC meeting in Leipzig showed comparable mortality rates with paclitaxel-eluting devices as comparable non-drug-eluting devices.

Results Recap: Medtronic Highlights Data To Contrast With Recent Meta-Analysis That Sparked Drug-Coated Balloon Scrutiny

This week's edition of Medtech Insight's Results Recap, the weekly roundup of major device trial-results from MedDeviceTracker, includes medical device trial results announced from Jan. 11 through Jan. 24. This week's list is dominated by results presentations from the Leipzig Interventional Course (LINC) in Leipzig, Germany, including trials of devices from Medtronic, Boston Scientific, Gore, Profusa, InspireMD, and Vessi.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel